black box warning semaglutide FDA warns about safety of 'off-brand' versions of Ozempic, Wegovy GLP-1 Weight Loss Medications |

Novo Nordisk the company behind Ozempic, Wegovy and Rybelsus reported $31.1 billion in revenue from the medications in 2024, up from $11.9 billion in 2022

Additionally, by improving insulin resistance and adipose-driven inflammation, GLP-1 agonists may reduce metabolic contributors that further perpetuate HS activity

Originally developed as a treatment for diabetes, uptake has been staggering since the drugs were approved for weight loss, reflecting GLP-1s efficacy and growing acceptance

These experiences are expected as your metabolic pathways reset

A key part of this will be the SURMOUNT-Real UK study, which will look at the effects of tirzepatide in a primary care setting on weight loss, prevention of obesity-related conditions, health-related quality of life, and changes in employment status and sick day absences, compared with usual care over 5 years